<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801541</url>
  </required_header>
  <id_info>
    <org_study_id>CNTM326_A9010002</org_study_id>
    <nct_id>NCT00801541</nct_id>
  </id_info>
  <brief_title>Characterization of Early Markers of Choroidal Neovascularization</brief_title>
  <acronym>CNV-Markers</acronym>
  <official_title>Characterization of Early Markers of Choroidal Neovascularization in Fellow Eyes of Patients With AMD and CNV in One Eye. (CNV-Markers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association for Innovation and Biomedical Research on Light and Image</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association for Innovation and Biomedical Research on Light and Image</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To this study and identify the sequence of alterations occurring in the chorioretinal&#xD;
      interface during progression of AMD from &quot;dry&quot; AMD to sight-threatening chorioretinal&#xD;
      neovascularization (CNV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary statistical objective of this study is to identify the sequence of alterations&#xD;
      occurring in the chorioretinal interface during progression of AMD from risk &quot;dry&quot; AMD to&#xD;
      sight-threatening chorioretinal neovascularization (CNV) (wet AMD).&#xD;
&#xD;
      Different imaging methods will be used simultaneously and at regular intervals in order to&#xD;
      characterize markers or predictors of conversion to sight-threatening CNV will be: CNV&#xD;
      (classic or occult) or position of CNV within 2500 µm (~1.7 disc diameters) of the foveal&#xD;
      center, as evidenced by fluorescein angiography.&#xD;
&#xD;
      This is an institutional, prospective, observation study to be performed in fellow eyes of&#xD;
      patients with evidence of &quot;wet&quot; AMD in other eye. Therefore, patients will have evidence of&#xD;
      exudative (&quot;wet&quot;) AMD in one eye ( the non-study eye) and non-exudative (&quot;dry&quot;) AMD in the&#xD;
      fellow eye (the study eye) that is at risk for progressive to exudation &quot;wet&quot; CNV.&#xD;
&#xD;
      Patients will exit the study at the time of developing sight-threatening CNV in the study eye&#xD;
      and will be treated at the discretion of the physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wet AMD development in the study eye.</measure>
    <time_frame>Single Visit</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>AMD</arm_group_label>
    <description>Patients with wet AMD in one eye and dry AMD in the other eye (study eye).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of either sex, any race, aged over 50 years and over, diagnosed with exudative&#xD;
        (wet) AMD in one eye (non-study eye) and non-exudative (dry) AMD (intermediate or&#xD;
        large/confluent drusen, with hyperpigmentation, and no CNV or geographic atrophy) in the&#xD;
        other eye (study eye) that is at risk for progressing to exudative (wet) AMD and meet all&#xD;
        the inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age over 50 years&#xD;
&#xD;
          -  Any race and any sex&#xD;
&#xD;
          -  Clinical diagnosis of exudative AM;D in one eye (non-stud eye) and the presence of the&#xD;
             following characteristics in the second eye (study eye, eye to be treated):&#xD;
&#xD;
               -  At least 5 or more intermediate (&gt; 63 µm) or larger soft drusen AND/OR Confluent&#xD;
                  drusen within 3000 µm of the fovea center&#xD;
&#xD;
               -  Hyperpigmentation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of medical condition that would preclude scheduled study visits&#xD;
&#xD;
          -  History of ophthalmic disease in the study eye other than AMD&#xD;
&#xD;
          -  Clinical signs of myopic retinopathy, or refraction higher than -8 diopter power.&#xD;
&#xD;
          -  Intraocular surgery in the study eye within 60 days prior enrollement&#xD;
&#xD;
          -  Evidence of past or present CNV in the study eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Cunha-Vaz, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association for Innovation and Biomedical Research on Light and Image</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIBILI - Clinical Trial Center</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>http://www.aibili.pt</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

